Skip to content
Precision for Medicine
Contact Us
false false
Chicago - shrinked

Friday, May 30 - Tuesday, June 3

ASCO 2025

Booth #11059

Join our executive team and experts in Chicago

Accelerate your oncology development with a purpose-built, integrated CRO. Precision combines scientific expertise with responsive operations across 2,500+ completed trials. Our comprehensive lab and clinical solutions transform your cancer innovations into life-changing therapies, delivering faster, cost-efficient results.

Drop by our booth #11059 or complete the form below to book a meeting with our experts at ASCO.

Sofia Baig, President, Clinical Solutions

The Precision difference

At Precision, we are committed to being the most reliable CRO in the industry, delivering on our promises with unwavering expertise and transparency. Our team excels in handling complex trials in oncology, fostering innovation and cross-functional collaboration to accelerate development timelines. By investing in next-generation technologies, we enhance clinical data access, improve decision-making, and streamline processes. This commitment helps deliver life-changing therapies efficiently, making Precision a trusted partner in advancing medicine and shaping the future of medicine.

Meet our executive leaders

  • Margaret Keegan

    Margaret Keegan

    Chief Executive Officer, Precision Medicine Group

  • Chad_Clark_Resize

    Chad Clark

    President and Chief Operating Officer, Precision Medicine Group

  • Matt Grow 1

    Matt Grow

    Chief Commercial Officer, Precision for Medicine

  • Matt-Arnold-1

    Matt Arnold

    President, Translational Sciences, Precision for Medicine

  • Harpreet-Singh2

    Harpreet Singh, MD

    Chief Medical Officer, Precision for Medicine

  • Deb Phippard

    Deborah Phippard, PhD

    Chief Scientific Officer, Precision for Medicine

  • Darren Davis

    Darren Davis, PhD

    Senior Vice President, Translational Sciences, Precision for Medicine

  • Andrea Cotton

    Andrea Cotton-Berry

    Global Head of Strategic Development, Precision for Medicine

Book time with our experts! 

Contact us using the form below and our team will reach out to set up a dedicated meeting time at ASCO.  

Find Precision for Medicine at booth #11059

ASCO 2025

McCormick Place, 2301 S Martin Luther King Dr, Chicago, IL 60616, United States

Exhibiting hours:

May 31 – June 2 - 09:00AM - 05:00PM

Harpreet Singh, MD, CMO and Former FDA Oncology Division Director

FDA approvals revolutionizing cancer research

2024 was a remarkable year for cancer and rare disease treatments, with the FDA approving several new and innovative therapies. In this video, Precision’s Chief Medical Officer and Former FDA Oncology Division Director, Harpreet Singh, MD, shares the top three approvals that will drive cancer treatment advancements in 2025.

Enhance early phase oncology with seamless phase 1-2 designs

Precision's cross-functional experts have executed 46 seamless oncology trials in the past 3 years. This eBook contains key considerations and best practices that are grounded in real-world experience to help you navigate the road ahead.

  • Prestudy Strategy & Planning
  • Execution Strategies
  • Selecting a CRO

 

Download eBook

Oncology development insights from Precision experts

Stay informed with the latest insights from our experts, who share knowledge, trends, and success stories from the forefront of clinical research.

Discover more
Read: Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

Progress in Gastrointestinal Oncology: 5 Key Insights from ASCO GI

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=178509987433, hs_child_table_id=0, hs_updated_at=1728330014032, hs_published_at=1748379090824, description=Ivan Barrera, MD is a fellowship-trained expert in Research GI Oncology with over 15 years of clinical research experience across various healthcare systems and facilities. He is a methodical and strategic key player in interdisciplinary drug development teams, specializing in medical monitoring. Dr. Barrera has extensive experience in solid tumors, particularly Gastrointestinal Oncology, including Neuroendocrine Tumors, and has worked on FIH and Phase I-IV studies. His industry clinical development experience spans small molecules, antibodies, vaccines, cytokines, oncolytic viruses, radiopharmaceuticals, and cellular therapies., avatar=Image{width=685,height=649,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Ivan%20Barrera.jpg',altText='Ivan Barrera',fileId=180445483936}, lastname=Barrera, hs_initial_published_at=1726512636738, hs_created_by_user_id=26433386, hs_created_at=1726500269983, hs_is_edited=false, hs_deleted_at=0, name=Ivan, job=Senior Medical Director, slug=ivan-barrera, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Ivan Barrera avatar

    Ivan Barrera
Discover
Read: Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

Clinical Trials - Early Phase Research - Oncology

Phase 1-2 Case Study: Oncology Trial Success and Proactive Partnership

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=169565849889, hs_child_table_id=0, hs_updated_at=1723217264651, hs_published_at=1748379090824, avatar=Image{width=320,height=314,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Tai%20Bibbs.jpg',altText='Tai Bibbs',fileId=168843139243}, lastname=Bibbs, hs_initial_published_at=1718988967067, hs_created_by_user_id=26433386, hs_created_at=1717603645564, hs_is_edited=false, hs_deleted_at=0, name=Tai, job=Director, Project Management, slug=tai-bibbs, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Tai Bibbs avatar

    Tai Bibbs
Discover
Read: FDA's Vision for Multiregional Clinical Trials in Oncology FDA's Vision for Multiregional Clinical Trials in Oncology

Clinical Trials - Regulatory - Oncology

FDA's Vision for Multiregional Clinical Trials in Oncology

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=167363064857, hs_child_table_id=0, hs_updated_at=1719905898183, hs_published_at=1748379090824, description=Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors., avatar=Image{width=553,height=580,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Harpreet-Singh2.png',altText='Harpreet-Singh2',fileId=171747124346}, linkedin=https://www.linkedin.com/in/harpreetsinghmd/, team=[{id=163072475007, name='Precision for Medicine Leadership'}], lastname=Singh, MD, hs_initial_published_at=1715692570942, hs_created_by_user_id=2737751, hs_created_at=1715692477118, hs_is_edited=false, hs_deleted_at=0, name=Harpreet, job=Chief Medical Officer, slug=harpreet-singh, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Harpreet Singh, MD avatar

    Harpreet Singh, MD
Discover

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Incorporate manufacturing expertise for advances therapies to ensure scalability. Precision can customize and converge our capabilities for your program's unique needs.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore

Margaret Keegan
Margaret Keegan

Chief Executive Officer, Precision Medicine Group

Industry luminary, passionate about building tech-enabled and data-driven operational models that streamline development and access for much needed medicines. Former leader at the world’s largest and most successful CROs, as COO at PRA Health Services and President of IQVIA Clinical Development. Expert in the full range of clinical development functions including biostatistics, data, safety, regulatory, clinical development, and sales. Driven to enable leaders and teams to be their best and to deliver with excellence for our clients and the patients we serve.
Chad_Clark_Resize
Chad Clark

President and Chief Operating Officer, Precision Medicine Group

Recognized industry leader with deep expertise spanning biomarker-driven clinical development, patient access and global market access. In addition to the role at Precision Medicine Group, Chad is also President of Precision for Medicine. In prior roles he has served as Chief Operating Officer of United BioSource Corporation and founder of DataPhaseIV. Proven ability to scale operations in response to client needs, adding the end-to-end capabilities necessary to support development and patient access to today’s complex therapies.
Matt Grow 1
Matt Grow

Chief Commercial Officer, Precision for Medicine

Visionary leader with a strong track record of fostering growth through commercial innovation and excellence. Drives sales by evolving the go-to-market model, landing and expanding key customer segments, and strengthening active client relationships. Proven expertise in biotech and pharmaceutical development spanning executive management, strategy, business development, sales, marketing and account management.
Matt-Arnold-1
Matt Arnold

President, Translational Sciences, Precision for Medicine

Strategic, highly collaborative biotechnology industry veteran, driven by opportunities to bring life-changing therapeutics to patients. Over two decades of global, cross-functional biotech and pharmaceutical experience, across both rapid growth and mature organizations, including leadership positions at AVROBIO, AstraZeneca, and Amgen.
Harpreet-Singh2
Harpreet Singh, MD

Chief Medical Officer, Precision for Medicine

Industry-leading oncologist and demonstrated medical leader in precision medicine, novel trial design and innovative regulatory initiatives designed to expedite drug approvals. Draws on nearly a decade leading oncology and rare disease programs at the FDA. Former fellow at the National Cancer Institute and frequent featured speaker at ASCO and AACR. CDER technical authority on oncologic drug and biological products for thoracic and head and neck malignancies, neurologic tumors, pediatric solid tumors and rare tumors.
Deb Phippard
Deborah Phippard, PhD

Chief Scientific Officer, Precision for Medicine

Pharma industry veteran and expert at biomarker-driven clinical trial design and execution. Leader of biomarker and drug development programs for pharmaceutical and diagnostics companies, as well as the National Institutes of Health. Spearheaded the discovery of pharmacodynamic biomarkers and novel targets for inflammatory disease therapy.
Darren Davis
Darren Davis, PhD

Senior Vice President, Translational Sciences, Precision for Medicine

Visionary leader with decades of distinguished biotechnology and clinical translational research experience. Founded ApoCell in 2004 and later was instrumental in developing and commercializing the ApoStream® rare-cell liquid biopsy technology. Globally recognized cancer researcher and the author of more than 100 peer-reviewed publications. Dedicated and committed to improving the lives of patients with debilitating diseases.
Andrea Cotton
Andrea Cotton-Berry

Global Head of Strategic Development, Precision for Medicine

Notable authority in global operations, dedicated to fostering team spirit of excellence and collaboration with internal and external partners. Veteran of the quest to improve oncology therapies and extend lives, including 15+ years in oncology drug development, building on 10 years in obstetrics and women’s health.